- Tytuł:
-
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and
dexamethasone in relapsed and refractory multiple myeloma. - Autorzy:
- Źródło:
- European journal of haematology [Eur J Haematol] 2021 Sep; Vol. 107 (3), pp. 333-342. Date of Electronic Publication: 2021 Jun 23.
- Typ publikacji:
- Clinical Trial, Phase II; Journal Article
- MeSH Terms:
-
Cost of Illness*
Costs and Cost Analysis*
Antineoplastic Combined Chemotherapy Protocols/*economics
Cyclophosphamide/*economicsDexamethasone /*economics
Multiple Myeloma/*economics
Oligopeptides/*economics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Canada ; Cyclophosphamide/therapeutic use ;Dexamethasone /therapeutic use ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Oligopeptides/therapeutic use ; Patient Acceptance of Health Care/statistics & numerical data ; Recurrence ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe